Guglielmo Beccuti
Overview
Explore the profile of Guglielmo Beccuti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
887
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bombonato M, Beccuti G, Benso A, Giannone B, Bertaina S, Broglio F, et al.
Hormones (Athens)
. 2025 Feb;
PMID: 39903441
Background: Sulfonylureas constitute the standard therapy for patients with HNF1A-MODY (maturity-onset diabetes of the young) but are characterized by an increased risk of hypoglycemia. While SGLT2 inhibitors (SGLT2i) may potentially...
2.
Zaccardi B, Armandi A, Caviglia G, Broglio F, Vernero M, Bombonato M, et al.
J Clin Med
. 2025 Jan;
14(1.
PMID: 39797226
The characterization of patients with inflammatory bowel disease (IBD) and type 2 diabetes mellitus (T2DM) as a new group has not been well detailed. This study aimed to evaluate the...
3.
Beccuti G, Bioletto F, Parasiliti-Caprino M, Benso A, Ghigo E, Cicolin A, et al.
Curr Obes Rep
. 2024 Oct;
13(4):739-742.
PMID: 39378016
Purpose Of Commentary: This commentary aims to offer a perspective on the effect of tirzepatide on hypoxic burden and provide indirect evidence of cardiovascular risk reduction after tirzepatide for the...
4.
Zizzi C, Dolla C, Fop F, Mella A, Sandrone M, Ghigo E, et al.
Kidney Int Rep
. 2024 Mar;
9(3):707-711.
PMID: 38481492
No abstract available.
5.
Egalini F, Rossi M, Massussi M, Gaggero G, Beccuti G, Benso A, et al.
Endocr Metab Immune Disord Drug Targets
. 2023 Dec;
24(6):651-663.
PMID: 38083891
In recent years, scientific research has increasingly focused on the cardiovascular benefits of omega-3 polyunsaturated fatty acids (n-3 PUFAs) supplements. The most promising results emerged from the new trials on...
6.
Egalini F, Guardamagna O, Gaggero G, Varaldo E, Giannone B, Beccuti G, et al.
Nutrients
. 2023 Jun;
15(12).
PMID: 37375575
Massive changes have occurred in our diet. A growing consumption of vegetal oils rich in omega-6 (ω-6) and a depletion of omega-3 (ω-3) fatty acids (FAs) in our food has...
7.
Bioletto F, Lopez C, Bollati M, Arata S, Procopio M, Ponzetto F, et al.
Front Endocrinol (Lausanne)
. 2023 May;
14:1145186.
PMID: 37223051
Background: The systematic use of confirmatory tests in the diagnosis of primary aldosteronism (PA) increases costs, risks and complexity to the diagnostic work-up. In light of this, some authors proposed...
8.
Lopez C, Bima C, Bollati M, Bioletto F, Procopio M, Arata S, et al.
Int J Mol Sci
. 2023 Mar;
24(6).
PMID: 36982228
Glycemic alterations are frequent in patients with pheochromocytoma and paraganglioma (PPGL), but the real incidence of secondary diabetes mellitus (DM) is uncertain, because prospective multicenter studies on this topic are...
9.
Nowotny H, Bryce J, Ali S, Giordano R, Baronio F, Chifu I, et al.
Endocr Connect
. 2023 Jan;
12(4).
PMID: 36715679
Background: Information on clinical outcomes of coronavirus disease 19 (COVID-19) infection in patients with adrenal disorders is scarce. Methods: A collaboration between the European Society of Endocrinology (ESE) Rare Disease...
10.
Viglino F, Sellami M, Broglio F, Scuntero P, Padovan A, Maulini C, et al.
J Pers Med
. 2022 Dec;
12(11).
PMID: 36579585
Background: Lipodystrophy is one of the most frequent complications in people with diabetes following subcutaneous insulin therapy, and poor management can lead to several problems, such as impaired glycemic control...